Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Benitec Biopharma (BNTC) over the last 1 years, with Jun 2025 value amounting to $2.5 million.

  • Benitec Biopharma's Cash from Financing Activities fell 93.65% to $2.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $70.5 million, marking a year-over-year decrease of 16.13%. This contributed to the annual value of $70.5 million for FY2025, which is 3.61% up from last year.
  • Benitec Biopharma's Cash from Financing Activities amounted to $2.5 million in Q2 2025, which was down 91.05% from $28.4 million recorded in Q1 2025.
  • Benitec Biopharma's 5-year Cash from Financing Activities high stood at $40.1 million for Q2 2024, and its period low was $3,000 during Q1 2021.
  • For the 3-year period, Benitec Biopharma's Cash from Financing Activities averaged around $19.8 million, with its median value being $21.7 million (2024).
  • As far as peak fluctuations go, Benitec Biopharma's Cash from Financing Activities spiked by 45,720.51% in 2024, and later crashed by 93.65% in 2025.
  • Quarterly analysis of 5 years shows Benitec Biopharma's Cash from Financing Activities stood at $12.7 million in 2021, then reached $16.0 million in 2022, then spiked by 74.33% to $39,000 in 2023, then spiked by 45,720.51% to $17.9 million in 2024, then crashed by 93.65% to $2.5 million in 2025.
  • Its Cash from Financing Activities stands at $2.5 million for Q2 2025, versus $28.4 million for Q1 2025 and $17.9 million for Q4 2024.